CD274 and vulva cancer: The KEYNOTE-028 basket Ph Ib trial underscored the anti-tumor effects of pembrolizumab in diverse PD-L1 positive, advanced, solid tumors with a 6% objective response rate (ORR) seen in 18 vulvar cancer patients on that trial [58].